Common molecular basis for MASH and hepatitis C revealed via systems biology approach
We extracted 10 hub genes between MASH and hepatitis C, and performed a series of analyses on the genes. Molecular docking and <i>in vitro</i> studies have revealed that Budesonide can effectively suppress the progression of MASH and hepatitis C. This study can provide novel insights into the potential drug targets and biomarkers for MASH and hepatitis C.
Authors
- Zihao Song (ORCID: https://orcid.org/0000-0002-2899-257X)
- Xichao Xu
- Yifan Cheng (ORCID: https://orcid.org/0000-0003-2312-093X)
- Yuan-Chuan Zou (ORCID: https://orcid.org/0000-0002-5400-3261)
- Wenwen Li (ORCID: https://orcid.org/0000-0001-9806-5045)
- Ye Liu (ORCID: https://orcid.org/0000-0003-0841-9263)
- Dali Zhang (ORCID: https://orcid.org/0000-0003-4311-5804)
- Dongling Dai (ORCID: https://orcid.org/0000-0003-4808-3418)
- Yinzhen Zeng
- D. Bai
- Liang Liu
Institutions
- Hubei University of Chinese Medicine (CN)
- Shenzhen Children's Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-04
- DOI
- https://doi.org/10.3389/fonc.2024.1442221
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shenzhen Science and Technology Innovation Program